1 / 4

Hepatocellular Carcinoma Drugs Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

Hepatocellular carcinoma (HCC) is a major type of primary liver cancer that arises from the liver cells or hepatocytes.<br>

rajkumarbisen
Download Presentation

Hepatocellular Carcinoma Drugs Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hepatocellular Carcinoma Drugs Market - Global Industry Hepatocellular Carcinoma Drugs Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026 2018-2026 Hepatocellular carcinoma (HCC) is a major type of primary liver cancer that arises from the liver cells or hepatocytes. The disease is found to occur mainly in patients with hepatitis B, hepatitis C, cirrhosis, obesity, and diabetes. Diagnosis of hepatocellular carcinoma is mainly done by imaging tests such as ultrasound, MRI, CT scan, and liver biopsy. Treatment for hepatocellular carcinoma mainly includes radiation therapy, ablation therapy in addition to chemotherapy and targeted drug therapy. A majority of the HCC patients are diagnosed at the end-stage of liver dysfunction. Due to poor prognosis of the condition, mortality rate is approximately the same as the incidence rate. Therefore, early detection of the cancer is an important parameter to improve the survival of affected patients, thus aiding in growth of the global hepatocellular carcinoma drugs market. Request Sample Copy of Research Report: Request Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1596 https://www.coherentmarketinsights.com/insight/request-sample/1596 Market Dynamics Market Dynamics Increasing incidence of global hepatocellular carcinoma cases is a major factor augmenting market growth. According to the research by International Journal of Cancer Research and Treatment, 2014, HCC is the sixth most common type of cancer worldwide and third most common cause of death worldwide, fifth for men and eighth for women. The disease accounts for more than 5% of all cancers and for 80-90% of primary liver cancers. Also, according to the Addis Ababa University, 2017, hepatocellular carcinoma (HCC) accounted to 854,000 new cases of liver cancer and 810,000 related deaths in 2015. Furthermore, increasing incidence and mortality of hepatocellular carcinoma is attributed to the emergence of new risk factors such as hepatitis B and C viral infections, metabolic disorders such as diabetes and non-alcoholic fatty liver disease, and exposure to toxins such as alcohol and aflatoxin.

  2. Regional Dynamics Regional Dynamics Regional segmentation of the global hepatocellular carcinoma drugs market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global hepatocellular carcinoma drugs market over the forecast period, owing to increasing prevalence of the disease and the rising number of clinical trials undertaken by the manufacturers to address the unmet medical needs of the patients. According to the survey by the Health Science Department, University of California, Los Angeles, (UCLA), 2017, hepatocellular carcinoma (HCC) accounts for three quarters of liver cancers in the U.S. with an estimated 40,000 Americans diagnosed with liver cancer in 2017 and more than 28,000 deaths are reported from the disease. Also, in April 2018, Eli Lilly and Company completed Phase 3 research study of Cyramza (ramucirumab) as a single agent in the second-line treatment of people with hepatocellular carcinoma, also known as liver cancer. Key players operating in the global hepatocellular carcinoma drugs market include Novartis Key players operating in the global hepatocellular carcinoma drugs market include Novartis Pharmaceuticals, Bayer AG, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Pharmaceuticals, Bayer AG, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson, Celgen Corporation, Amgen Inc., Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Celgen Corporation, Amgen Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. Report includes chapters which deeply display the following deliverable about industry : Report includes chapters which deeply display the following deliverable about industry : • Hepatocellular Carcinoma Drugs Market Research Objective and Assumption • Hepatocellular Carcinoma Drugs Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Hepatocellular Carcinoma Drugs Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Hepatocellular Carcinoma Drugs Market, By Regions • Hepatocellular Carcinoma Drugs Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Hepatocellular Carcinoma Drugs Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Hepatocellular Carcinoma Drugs Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List.

  3. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Hepatocellular Carcinoma Drugs Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Inquire Here Before Purchase: Inquire Here Before Purchase: https://www.coherentmarketinsights.com/insight/talk-to-analyst/1596 https://www.coherentmarketinsights.com/insight/talk-to-analyst/1596 Market Taxonomy Market Taxonomy On the basis of drug class, global hepatocellular carcinoma drugs market is segmented into: • PD-1/PD-L1 Inhibitors • Nivolumab (Opdivo) • Tyrosine Kinase Inhibitors • Sorafenib (Nexavar) • Regorafenib (Stivarga) On the basis of end user, the global hepatocellular carcinoma drugs market is segmented into: • Hospital • Clinics • Cancer Rehabilitation Centers • Ambulatory Surgical Centers About Coherent Market Insights About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action- ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Contact Us Mr. Shah

  4. Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: Email: sales@coherentmarketinsights.com sales@coherentmarketinsights.com

More Related